Bharat Biotech International Limited on Thursday announced the launch of India’s only vertically integrated, purpose-designed Cell & Gene Therapy (CGT) Infrastructure and Viral Vector Production Facility at Genome Valley in Hyderabad.
“This facility ushers in a new era of gene and cell therapies to tackle scientific challenges—such as targeted gene expression, immune system modulation, and long-term cell survival— The work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like hemophilia,” the company said in a statement.
The company claims that the 50,000-square-foot dedicated CGT facility represents the next milestone in BBIL’s long-standing mission to deliver targeted, life-saving treatments that address unmet clinical needs globally by concentrating on critical conditions such as hematological malignancies and inherited blood disorders.
“Gene and cell therapies represent some of the most intricate, scientifically advanced treatments available today, involving sophisticated processes that require expertise in precise genetic manipulation and specialized manufacturing capabilities. Bharat Biotech, with its extensive experience and proven excellence in viral vaccine manufacturing is uniquely positioned to master these complexities and produce human-grade vectors at the scale and consistency needed for clinical trials, thus advancing the global fight against rare and complex diseases,” Dr. Krishna Ella, Executive Chairman, Bharat Biotech said.
Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said that oncology and rare diseases treatment therapies are their key focus areas.
“This the facility will support a wide array of advanced therapies, including CD19 CAR T Cell Therapy for Blood cancers and Gene Therapy. Leveraging this deep expertise, Bharat Biotech is not only bridging the gap between scientific innovation and mass affordability but also reaffirming its enduring commitment to democratizing healthcare for the nation and beyond,” Dr. Ella said.